Earnings analysis · 10-Q
TENX earnings analysis
Filed May 12, 2026 · Our reading of the company's report
The latest report
Tenax Therapeutics reported a challenging Q1 2026, with a net loss of $15.7 million, reflecting a significant increase in operating expenses primarily driven by rising R&D costs. The company's total cash position…
Read full summary
Tenax Therapeutics reported a challenging Q1 2026, with a net loss of $15.7 million, reflecting a significant increase in operating expenses primarily driven by rising R&D costs. The company's total cash position remains solid at $118.8 million, expected to fund operations until at least Q1 2028, despite a consistent trend of net losses across quarters.
Reported figures
- Earnings per share
- $-0.35
What stood out
-
Net Loss Increased
The net loss for Q1 2026 was $15.7 million, a $5.3 million increase compared to $10.4 million in Q1 2025.
-
R&D Expenses Surge
Research and development expenses rose by $5.8 million to $11.5 million in Q1 2026 from $5.7 million in Q1 2025.
-
Cash Position Solidified
Tenax Therapeutics maintained a cash position of $118.8 million, sufficient to fund operations through at least Q1 2028.
-
EPS Improvement
The diluted EPS for Q1 2026 was -$0.35, better than the consensus estimate of -$0.40.
-
Operating Cash Flow
Net cash used in operating activities amounted to $9.3 million in Q1 2026, compared to $7.0 million in Q1 2025.
-
Increased Financing Activities
Received $30.5 million from financing activities in Q1 2026, up from $23.6 million in Q1 2025.
What to watch
-
High Net Operating Loss
Net loss increased by 51% to $15.7 million in Q1 2026 from $10.4 million in Q1 2025.
-
Escalating R&D Costs
R&D expenses jumped by 102% year-over-year, increasing to $11.5 million in Q1 2026.
-
Clinical Trial Execution Risks
Continued reliance on successful completion of clinical trials, which are unpredictable and costly.
Management's outlook
No specific quantitative guidance provided.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.